Product correctly added to cart.

discount label
Flufenamic acid-d4
View 3D

Biosynth logo

Flufenamic acid-d4

CAS: 1185071-99-1

Ref. 3D-KXB07199

5mgTo inquire
10mgTo inquire
25mgTo inquire
50mgTo inquire
Estimated delivery in United States, on Tuesday 11 Feb 2025

Product Information

Name:
Flufenamic acid-d4
Description:

Flufenamic acid-d4 is a medicinal compound with potent anticancer properties. It has been shown to inhibit the growth of cancer cells by inducing apoptosis and inhibiting the activity of kinases that are involved in tumor development. Flufenamic acid-d4 has been used as an inhibitor in various studies on human and Chinese hamster ovary cells, showing promising results in reducing the proliferation of cancer cells. This compound is also commonly found in urine samples and has been studied for its potential as a diagnostic marker for certain cancers. With its potent anticancer properties, flufenamic acid-d4 holds great promise as a potential therapeutic agent for treating various types of cancer.

Notice:
Our products are intended for lab use only. For any other use, please contact us.
Brand:
Biosynth
Long term storage:
Notes:

Chemical properties

Molecular weight:
228.27 g/mol
Formula:
C5H16N4O4S
Purity:
Min. 95%
MDL:
Melting point:
Boiling point:
Flash point:
Density:
Concentration:
EINECS:
Merck:
HS code:

Hazard Info

UN Number:
EQ:
Class:
H Statements:
P Statements:
Forbidden to fly:
Hazard Info:
Packing Group:
LQ:

Technical inquiry about: 3D-KXB07199 Flufenamic acid-d4

Please use instead the cart to request a quotation or an order

If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.

* Mandatory fields.
Welcome to CymitQuimica!We use cookies to enhance your visit. We do not include advertising.

Please see our Cookies Policy for more details or adjust your preferences in "Settings".